港股異動 | 新秀麗(1910.HK)跌6.74% 四日累跌約15%
格隆匯9月22日丨全球最大品牌行李箱製造商新秀麗(1910.HK)跌6.74%,報7.61港元,四日累跌約15%,最新總市值109億港元。近日,歐洲多國的新冠肺炎疫情確診人數持續增加,歐洲多國相繼實施更嚴格社交距離限制。歐洲多國可能將會因二次疫情的暴發,再次採取嚴格防控措施。疫情可能再度引發出行恐慌,對旅遊業帶來巨大沖擊的同時,波及旅遊用品市場。新秀麗約60%的收入來自行李箱包,包括新秀麗在內的旅行用品品牌今年以來面臨銷量增長大幅放緩。新秀麗此前公告稱,上半年銷售淨額8.02億美元,同比減少54.3%;公司擁有人應占虧損9.74億美元,上年同期溢利4910萬美元

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.